



## Exercise of options and PDMR dealing

January 30, 2023

RNS Number : 21430

MaxCyte, Inc.

30 January 2023

MaxCyte, Inc.

("MaxCyte" or the "Company")

### Exercise of options, PDMR dealing and Total Voting Rights

**ROCKVILLE, MD, January 30, 2023** - MaxCyte (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that between 3 January 2023 and 5 January 2023, as per filings lodged with the SEC, Doug Doerfler, Chief Executive Officer, exercised options over 30,000 shares of common stock of \$0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 30,000 new shares of Common Stock issued pursuant to the Exercise ("New Common Stock"), were sold by Doug Doerfler at a price range between of \$5.04 and \$5.13 per Common Stock ("Sale"). The sold shares represent approximately 0.9% of Doug Doerfler's total equity and option holdings in the Company's stock capital, respectively.

Following the Exercise, Doug Doerfler holds a further 2,983,680 options over Common Stock. His holding of 333,197 shares of Common Stock representing 0.3% of the issued stock capital of the Company, remains unchanged.

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Doug Doerfler on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024.

#### Total voting rights

The 30,000 New Common Stock have been admitted to trading on AIM pursuant to the Block Listing announced by the Company on September 6, 2021. The New Common Stock will rank pari passu with the existing shares of common stock of the Company and will trade in the unrestricted line of Common Stock trading under the symbol MXCT. The total issued stock capital of the Company following the above will be 102,845,612 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

**MaxCyte Contacts:**

US IR Adviser

+1 415-937-5400

**Gilmartin Group**

[ir@maxcyte.com](mailto:ir@maxcyte.com)

David Deuchler, CFA

*Nominated Adviser and  
Joint Corporate Broker*

+44 (0)20 7886 2500

Panmure Gordon

Emma Earl / Freddy  
Crossley

Corporate Broking

Rupert Dearden

UK IR Adviser

+44 (0)203 709 5700

**Consilium Strategic  
Communications**

[maxcyte@consilium-  
comms.com](mailto:maxcyte@consilium-<br/>comms.com)

Mary-Jane Elliott

Chris Welsh

**About MaxCyte**

MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® technology, which facilitates complex engineering of a wide variety of cells. Our EXPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The EXPERT family of products includes: four instruments, the ATx®, STx® GTx® and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

Learn more at [maxcyte.com](http://maxcyte.com) and follow us on [Twitter](#) and [LinkedIn](#).

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.		
1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Doug Doerfler

2	<b>Reason for the notification</b>									
a)	Position/status	Chief Executive Officer								
b)	Initial notification /Amendment	Initial Notification								
3	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>									
a)	Name	MaxCyte, Inc.								
b)	LEI	54930053YHXULRFCU991								
4	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>									
a)	Description of the financial instrument, type of instrument  Identification code	\$0.01 ordinary shares  US57777K1060								
b)	Nature of the transaction	Exercise of options over Common Stock								
c)	Price(s) and volume(s)	\$0.04 per Ordinary Share <table border="1" data-bbox="553 1010 1203 1255"> <thead> <tr> <th>Price(s)</th> <th>Volumes(s)</th> </tr> </thead> <tbody> <tr> <td>N/A</td> <td>10,613</td> </tr> <tr> <td>N/A</td> <td>9,153</td> </tr> <tr> <td>N/A</td> <td>10,234</td> </tr> </tbody> </table>	Price(s)	Volumes(s)	N/A	10,613	N/A	9,153	N/A	10,234
Price(s)	Volumes(s)									
N/A	10,613									
N/A	9,153									
N/A	10,234									
d)	Aggregated information  - Aggregated volume  - Price	30,000  N/A								
e)	Date of the transaction	3 to 5 January 2023								
f)	Place of the transaction	London Stock Exchange- AIM								

**Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.**

1	<b>Details of the person discharging managerial responsibilities / person closely associated</b>
---	--

a)	Name	Doug Doerfler								
2	<b>Reason for the notification</b>									
a)	Position/status	Chief Executive Officer								
b)	Initial notification /Amendment	Initial Notification								
3	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>									
a)	Name	MaxCyte, Inc.								
b)	LEI	54930053YHXULRFCU991								
4	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>									
a)	Description of the financial instrument, type of instrument  Identification code	\$0.01 ordinary shares  US57777K1060								
b)	Nature of the transaction	Sale of Common Stock								
c)	Price(s) and volume(s)	\$0.04 per Ordinary Share <table border="1" data-bbox="553 1102 1203 1346"> <thead> <tr> <th>Price(s)</th> <th>Volumes(s)</th> </tr> </thead> <tbody> <tr> <td>\$5.13</td> <td>10,613</td> </tr> <tr> <td>\$5.07</td> <td>9,153</td> </tr> <tr> <td>\$5.04</td> <td>10,234</td> </tr> </tbody> </table>	Price(s)	Volumes(s)	\$5.13	10,613	\$5.07	9,153	\$5.04	10,234
Price(s)	Volumes(s)									
\$5.13	10,613									
\$5.07	9,153									
\$5.04	10,234									
d)	Aggregated information  - Aggregated volume  - Price	N/A  30,000  \$5.08								
e)	Date of the transaction	3 to 5 January 2023								
f)	Place of the transaction	London Stock Exchange- AIM								

may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCEADFNAEPDEAA